DOE, FDA Announce Sufficient Mo-99 Medical Isotope Supply for Medical Diagnostic Procedures - Drug Information Update

If your email program has trouble displaying this email, view it as a web page. DOE, FDA Announce Sufficient Mo-99 Medical Isotope Supply for Medical Diagnostic Procedures The Radiopharmaceutical Supply Work Group within the FDA's Center for Drug Evaluation and Research (CDER) has been working with the Department of Energy (DOE) and DOE's National Nuclear Security Administration to achieve a stable domestic supply of the medical isotope molybendum-99 (Mo-99), which is essential to create drugs for medical diagnostic procedures. Today, DOE announced the national supply of Mo-99 can now meet demand, and the U.S. no longer has to rely on international partners to process highly enriched uranium to produce Mo-99 for domestic use. CDER's work to approve new drugs and production methods for Mo-99 has been instrumental in achieving this milestone. Starting in 2011, these new methods modernized more than six decades of commercial production technology, meeting domestic supply needs without using highly enriched uranium. We are excited to share the DOE's announcement with our stakeholders at FDA. Learn More This is an automated message delivery system. Replying to this message will not reach DDI staff. If you have comments or questions, please contact us at: 1-888-INFO- FDA (1-888-463-6332) or 301-796-3400 from 8:00 am - 4:30 pm ET Monday - Friday. You can also email us at: druginfo@fda.hhs.gov. Stay Connected with U.S. Food and Drug Administration:         SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA